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Hydroxychloroquine (HCQ) is an important chiral drug used, mainly, in the treatment of rheumatoid 
arthritis, systemic lupus erythematosus and malaria, and whose pharmacokinetic and pharmacodynamic 
properties look to be stereoselective. Respecting the pharmacokinetic properties, some previous studies 
indicate that the stereoselectivity could express itself in the processes of metabolism, distribution and 
excretion and that the stereoselective metabolism looks to be a function of the studied species. So, the in 
vitro metabolism of HCQ was investigated using hepatic microsomes of rats and mice. The microsomal 
fraction of livers of Wistar rats and Balb-C mice was separated by ultracentrifugation and 500 mL were 
incubated for 180 minutes with 10 mL of racemic HCQ 1000 mg mL-1. Two stereospecific analytical 
methods, high performance liquid chromatography (HPLC) and capillary electrophoresis (CE), were 
used to separate and quantify the formed metabolites. It was verified that the main formed metabolite is 
the (-)-(R)-desethyl hydroxychloroquine for both animal species.
Uniterms: Hydroxychloroquine. Stereoselective metabolism/in vitro study. High performance liquid 
chromatography. Capillary electrophoresis.
A hidroxicloroquina (HCQ) é um importante fármaco quiral usado, principalmente, no tratamento 
de artrite reumatóide, lupus eritematoso sistêmico e malária e cujas propriedades farmacocinéticas e 
farmacodinâmicas parecem ser estereosseletivas. Em relação às propriedades farmacocinéticas, alguns 
estudos prévios indicam que a estereosseletividade pode se expressar nos processos de metabolismo, 
distribuição e excreção e que o metabolismo estereosseletivo parece ser função da espécie estudada. 
Sendo assim, o metabolismo in vitro da HCQ foi investigado usando microssomas de fígado de ratos 
e de camundongos. A fração microssômica de fígados de ratos Wistar e de camundongos Balb-C foi 
isolada por ultracentrifugação e 500 mL foram incubados por 180 minutos com 10 mL de HCQ racêmica 
1000 mg mL-1. Dois métodos analíticos estereoespecíficos, por cromatografia líquida de alta eficiência 
(HPLC) e eletroforese capilar (CE), foram usados para separar e quantificar os metabólitos formados. 
Verificou-se que o principal metabólito formado é o (-)-(R)-desetilidroxicloroquina para ambas as 
espécies de animais.
Unitermos: Hidroxicloroquina. Metabolismo estereosseletivo/estudo in vitro. Cromatografia líquida de 
alta eficiência. Eletroforese capilar. 
INTRODUCTION
The hydroxychloroquine (HCQ) has its use approved 
by FDA (Food and Drug Administration) for the treatment 
of inflammatory chronic diseases, such as rheumatoid 
arthritis, systemic lupus erythematosus (SLE) and also as 
antimalarial (Wolf, 2000). It is considered effective and 
safe, however, 0.5 to 3.5% of patients submitted to HCQ 
treatment exhibit retinal lesion. Another adverse effect less 
intense, but observed with higher frequency is the gastroin-
testinal toxicity (Hardman et al., 1996; Tanaka et al., 2004).
Its hepatic metabolism generates three active me-
tabolites, desethylchloroquine (DCQ), desethyl-hydro-
xychloroquine (DHCQ) and bis-desethyl-chloroquine 
(BDCQ), all of them chiral (Ducharme et al., 1995; Wey 
et al., 1995) (Figure 1).
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The antiarthritic and antimalarial properties of in-
dividual enantiomers of HCQ are unknown, although it 
has been estimated that, in rats, the (+)-(S)-enantiomer 
of chloroquine (CQ), a drug structurally similar to HCQ, 
presents higher antimalarial activity than (-)-(R)-CQ 
(Brocks et al., 1992).
The enantioselective pharmacokinetics and meta-
bolism of HCQ are not totally known as well (Brocks, 
Mehvar, 2003). The studies respecting kinetic disposition 
of HCQ have been developed in vivo, from the oral drug 
administration in human or animals (Brocks et al., 1992; 
Mclachlan et al., 1993; Iredale et al., 1993; Ducharme et 
al., 1994; Wainer et al., 1994; Mclachlan et al., 1994; Wey 
et al., 1995; Ducharme et al., 1995) and have shown the 
existence of stereoselective processes.
Ducharme et al. (1995) evaluated the enantiose-
lective kinetic disposition of HCQ in healthy humans 
submitted to a single oral dose of rac-HCQ and observed 
faster elimination of enantiomer (+)-(S)-HCQ (proportion 
R/S >1 in the plasma), probably due to a faster urinary 
excretion and/or more accentuated hepatic metabolism of 
this enantiomer. The metabolites derived from enantiomer 
(+)-(S) represented 80-90% of the dose recovered in urine. 
Metabolites in the blood were not detected.
Other studies were developed in patients with rheu-
matoid arthritis submitted to single or multiple doses of 
rac-HCQ (Mclachlan et al., 1993; Mclachlan et al., 1994). 
McLachlan et al. (1993) have also found, for all patients, 
higher amounts of (-)-(R)-HCQ, as in the plasma as in the 
total blood.
Ducharme et al. (1994) have evaluated total blood 
and plasma of rabbits submitted to multiple doses of rac-
HCQ and from every of the enantiomers separately. On 
occasion of rac-HCQ administration, higher amount of 
enantiomer (+)-(S) was found in the plasma, while in the 
total blood, the concentrations were inverted. Yet for se-
parate enantiomers, in total blood, it was observed higher 
amount of (-)-(R)-HCQ respecting to (+)-(S)-HCQ. The 
observations suggest that the (-)-(R)-HCQ enantiomer is 
rather concentrated by blood cellular components and once 
fixed, it would let the enantiomer (+)-(S) more available 
for the metabolism.
WEY et al. (1995) when studying the stereoselec-
tive kinetic disposition of HCQ and their metabolites 
in rats, obtained, in total blood and in tissues, a propor-
tion R/S >1 for the enantiomers of HCQ and <1 for the 
enantiomers of metabolites DCQ and DHCQ, indicating 
that the enantiomer (+)-(S)-HCQ is rather metabolized 
or excreted.
In a study with patients bearing SLE, proportions 
R/S <1 were obtained for the enantiomers of HCQ in urine 
and R/S in plasma (Brocks et al., 1992).
The data presented above show that the kinetic 
disposition of HCQ is stereoselective and that such 
stereoselectivity can express itself in the processes of 
metabolism, excretion or distribution and depend also on 
the species employed in the study. Therefore, to study the 
hepatic metabolism of HCQ separately, it was developed 
a methodology utilizing the microsomal fraction of livers 
and analytical methods making use of high performance 
liquid chromatography (HPLC) and capillary electro-
phoresis (CE) (Cardoso, Bonato, 2005; Cardoso et al., 
2006). Such methodology was, then, employed to study 
the metabolism of HCQ utilizing microsomal fractions of 
rats and mice livers.
MATERIAL AND METHODS
Standard-solutions
The standards of HCQ and of its metabolites, DCQ, 
DHCQ and BDCQ employed in the preparation of stan-
dard-solutions, were kindly provided by Sanofi-Winthrop 
Pharmaceuticals (New York, USA). The stock-solutions of 
HCQ, DCQ and DHCQ were prepared in the concentration 
of 1000 mg mL-1 in methanol:water (50:50, v/v). The work 
solutions, in the concentrations of 5, 10, 20, 50, 100 and 
200 mg mL-1 were obtained from dilutions, in the same 
solvent system. All the solutions were stored at -20 °C 
and protected from light.
FIGURE 1- HCQ and its metabolites.
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Equipments
The livers from animals were homogenized with 
a “Potter” type homogenizer, model MA 039, provided 
with a water circulator for temperature control, model 
MA 181 (Marconi, São Paulo, Brazil). The centrifugation 
steps were developed in a HIMAC CF 15D2 centrifuge 
(Hitachi, Tokyo, Japan) and in a BECKMAN XL-70 cen-
trifuge (Beckman, Carlsbad, USA). For the protein dosage 
it was utilized a spectrophotometer SPECTRONIC 20 
GENESYSTM (Spectronic Instruments, New York, USA). 
The incubations were developed in a heated bath with a 
Dubnoff stirrer (Marconi, São Paulo, Brazil).
The chromatographic analyses were developed in a 
Shimadzu chromatograph (Kyoto, Japan) constituted by a 
pump model LC-10AT VP, Rheodyne injector model 7725 
with sampler of 50 mL, an absorption detector in the visible 
ultraviolet (UV) model SPD-10A and an integrator model 
Chromatopac C-R6A. 
The electrophoretic analysis of HCQ enantiomers 
and of its three metabolites was developed in an equipment 
from Agilent Technologies, model 61600A (Waldbronn, 
Germany), constituted by an analyzer, an automatic sam-
pler, a detector by diodes arrangement and a system of 
data acquisition with the software Agilent ChemStation.
A Digimed pH meter from Digicrom Analítica, 
model DM-20 (São Paulo, Brazil) was employed to me-
asure the pH of aqueous solutions. In order to eliminate 
the air dissolved in the solutions, it was utilized a Thorton 
ultrasound, model Ultrasonic Cleaner (São Paulo, Brazil). 
In the preparation of standard-solutions and elec-
trolytes it was utilized an analytical balance Ohaus Corp. 
(Pine Brook, USA), model Adventurer.
In the procedure of preparation of samples, a hori-
zontal tubes stirrer (Pachane Ltda., Piracicaba, Brazil), 
model PA241; a vortex type tubes stirrer (Phoenix Equipa-
mentos Científicos, Araraquara, Brazil), model AT56 and 
an Excelsa Baby centrifuge (Fanem, São Paulo, Brazil), 
model 206 were utilized.
Solvents and reagents
The salts monobasic and dibasic potassium phos-
phate were obtained from Merck (Rio de Janeiro, Brazil). 
The Hepes was obtained from Sigma-Aldrich (Steinheim, 
Germany). The substances b-nicotinamide-adenine-dinu-
cleotide phosphate (NADP), glucose-6-phosphate, gluco-
se-6-phosphate dehydrogenase and bovine serum albumin 
96% were obtained from Sigma (St. Louis, USA). The 
sodium tartrate and the urea were obtained from J. T. Baker 
(Phillipsburg, USA) and the pentahydrate copper sulfate 
was obtained from Reagem (Rio de Janeiro, Brazil). The 
sodium deoxicolate was obtained from Thermo Separation 
Products (San Jose, USA). The water was purified with the 
system Milli-Q Plus (Millipore, Bedford, USA).
The solvents (all chromatography grade) utilized 
in the preparation of samples and in the chromatographic 
analyses were obtained from EM Science (Gibbstown, 
USA) (methanol, isopropanol and chloroform); from 
Mallinckrodt (Paris, USA) (hexane); from Omnisolv (Dar-
mstadt, Germany) (toluene) and from J. T. Baker (Phillip-
sburg, USA) (acetonitrile). The diethylamine, grade p. a., 
was obtained from Fluka (St. Gallen, Switzerland).
The reagent tris(hydroxymethyl)-aminomethane 
(grade p.a.) was obtained from J.T. Baker (Phillipsburg, 
USA). The hydroxypropyl b-CD was obtained from Aldri-
ch Chem. Co. (Milwaukee, USA) and the sulfated b-CD 
was obtained from Supelco (Bellefonte, USA).
The solutions used in the equipment of CE were 
daily filtered, in a MILLEX – HA filter with porosity of 
0.45 mm, obtained from MILLIPORE (Bedford, USA) and 
taken to ultrasound for degasification.
Animals
Male and adult Wistar rats and male Balb-C mice 
were utilized, weighing, respectively, from 180 to 200 g 
and from 20 to 30 g. The animals were obtained from Vi-
varium II of the Faculty of Pharmaceutical Sciences of Ri-
beirão Preto, classification SPF (Specific Pathogen Free).
Incubation Procedure
Isolation of microsomal fraction from liver homogenate
The animals, acclimatized at 25 °C with light cycles 
of 12 hours, were submitted to fasting for one night, before 
the experiments. At morning, the animals were anesthe-
tized with ether and their livers were submitted to perfu-
sion (Jones, 1987) with sodium chloride at 0.9% (m/v), 
washed with potassium chloride 0.154 mol L-1 (pH 7.4), 
triturated and homogenized (3 cycles) in a “Potter” type 
homogenizer. The homogenate was filtered through two 
layers of gauze to remove residual tissues and the volume 
was adjusted with the solution of potassium chloride in a 
way to obtain a suspension at 20% (m/v), approximate-
ly. The obtained suspension was centrifuged at 9,000 g 
for 15 minutes, at 4 °C. The residue was neglected and 
the supernatant was submitted to ultracentrifugation at 
100,000 g for 60 minutes, at 4 °C. Then, the supernatant 
was neglected and the resulting ‘pellets’ were washed and 
homogenized with buffer solution tris-HCl 0.15 mol L-1 
(pH 7.6) and again submitted to ultra-centrifugation at 
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100,000 g for 60 minutes, at 4 °C. The supernatant was 
neglected and the ‘pellets’ were homogenized with hepes 
buffer 1.25 mmol L-1 in KCl at 1.15% and stored at -70 °C 
(Von Bahr et al., 1980; Lake, 1987).
The proteins concentration in the microsomal frac-
tions was determined according Cain & Skilleter (1987).
Optimization of incubation conditions
All optimization tests (developed in triplicate) were 
done with isolate rat liver microsomes. Then, the samples 
were submitted to extraction procedure and analyzed by 
HPLC (Cardoso, 2005). To achieve the analytical curves, 
aliquots of 25 mL from racemic standard-solutions of me-
tabolites DCQ and DHCQ, in duplicate, were transferred 
to amber tubes of extraction with grind caps, containing 
500 mL of diluted white plasma. The concentrations of 
racemic standard-solutions of metabolites were 2, 5, 10, 
20, 50, 100 e 200 mg mL-1, resulting in concentrations in 
the microsomal fractions of 50, 125, 250, 500, 1250, 2500 
and 5000 ng mL-1 of every enantiomer.
In the initial procedures of microsomes incubation 
(adapted from in vitro technologies, 2001), every sample 
consisted of 500 mL of microsomal fraction, 240 mL of 
potassium phosphate 100 mmol L-1 (pH 7.4) and 10 mL of 
HCQ standard solution. The solution of incubation - NRS 
(NADPH regenerating system) – consisted of 1.7 mg mL-1 
of NADP, 7.8 mg mL-1 of glucose-6-phosphate and 1.5 
units/mL of glucose-6-phosphate dehydrogenase on a 
solution of sodium bicarbonate at 2%. The samples and 
the NRS solution were maintained in a double boiler for 
5 minutes. After this time, 250 mL of NRS solution were 
added to samples in order to start the reaction. At the end, 
the incubation was interrupted by the addition of 1 mL of 
acetonitrile and the samples were submitted to extraction 
and chromatographic analysis.
The incubation time (30, 90 e 180 minutes), the HCQ 
racemic concentration (200, 500 and 1000 mg mL-1) and 
the volume of microsomes (200, 300, 500 and 1000 mL) 
were optimized.
In order to evaluate the influence of employed anes-
thetics, the metabolism experiments were also done with 
samples of microsomes of rats anesthetized with 400 mL 
of intraperitoneal (ip) thiopental. Samples of microsomes 
of rats treated with the metabolism inducer phenobarbital 
(Masimirembwa, Hasler, 1994) were also incubated, with 
the purpose to verify if the metabolism would increase 
with the use of this inducer. Phenobarbital at 4 mg mL-1, 
in NaCl 0.9%, was injected at a dose of 50 mg/kg of rat 
body, for four consecutive days. At the fifth day, the liver 
microsomal fractions of these rats and of four control-rats 
(without the inducer administration) were isolated.
Samples preparation and chromatographic and 
electrophoretic analyses
For HPLC analysis, the samples were prepared by 
liquid-liquid extraction with chloroform and analyzed in 
a Chiralpak AD-RH column, with a hexane:isopropanol 
92:8 (v/v) mobile phase with 0.1% of diethylamine, in a 
wave length of 343 nm (Cardoso, Bonato, 2005).
For CE analysis, the samples were prepared by liquid-
liquid extraction with toluene and analyzed in a capillary 
of 42 cm (effective length) x 50 mm, at 20 °C, with buffer 
solution tris(hydroxymethyl)aminomethane 100 mmol L-1, 
pH 9.0, containing 1% of sulphated b-cyclodextrin and 
30 mmol L-1 of hydroxypropylated b-cyclodextrin, with 
detection in 220 nm (Cardoso et al., 2006).
The concentrations of enantiomers of formed me-
tabolites were determined from the analytical curves also 
submitted to extraction process.
Metabolism study
For the study of hepatic metabolism, microsomal 
fractions isolated from liver of Wistar rats and Balb-C 
mice were used, with protein concentrations of 30 to 
40 mg mL-1. The microsomal fractions isolated from rat 
liver were incubated with the racemic HCQ (500 mg mL-1 
of every enantiomer) and also with the isolated enantio-
mers (420 mg mL-1 of (-)-(R)-HCQ and 630 mg mL-1 of 
(+)-(S)-HCQ, approximately, obtained by semiprepara-
tive separation in HPLC); the determination of enantio-
mers of formed metabolites was developed by HPLC.
The microsomal fractions isolated from mice were 
incubated only with racemic HCQ (500 mg mL-1 of every 
enantiomer) and the analyses were developed by HPLC 
and CE.
RESULTS AND DISCUSSION
Optimization of incubation conditions
The choice of the better incubation conditions, i.e., 
incubation time, racemic HCQ concentration and volume 
of microsomal fraction, was done utilizing the “Tukey” 
test, which determines if there is, between the responses 
from evaluated conditions, a significant difference. Table 
I shows the average concentrations for every formed enan-
tiomer and the respective coefficient of variation, in the 
three optimization steps: A – incubation time, B – HCQ 
and C concentration – volume of microsomal fraction. In 
bold are emphasized the conditions that provided better 
production of metabolites.
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After optimization of incubation conditions, it was 
also evaluated the influence of employed anesthetic: 
ethylic ether or thiopental. The proteins dosage in micro-
somal fractions was of 63.6 mg mL-1 and 59.8 mg mL-1 
for the rats anesthetized with ether and thiopental, res-
pectively. Analyzing the obtained results (Table II), an 
option has been done for the utilization of ethylic ether 
as anesthetic, as a function of the higher concentration of 
produced metabolites.
It was also investigated, the in vitro metabolism in 
liver microsomal fractions of rats pretreated with pheno-
barbital, an inducer of CYP450 isoforms (Masimirembwa, 
Hasler, 1994). The investigation has shown only a mild 
increase in the concentration of metabolites in the micro-
somal fraction of animals pretreated with phenobarbital 
(Table II). Despite the increase in the concentration of 
enantiomers produced, for the majority of metabolites, the 
option was to work without the inducer, due to the fact that 
the utilization of it would imply in larger time spent with 
the experiments. The proteins dosage in both microsomal 
fractions was of 37.8 mg mL-1.
Table III presents the definitive conditions for the 
procedure of incubation.
Metabolism of HCQ employing the isolated 
microsomal fraction of rats liver
Once established the procedure to be employed in 
the metabolism process, it was developed a study of race-
mic HCQ metabolism (1000 mg mL-1) and also of isolated 
enantiomers of the drug (420 mg mL-1 of (-)-(R)-HCQ and 
630 mg mL-1 of (+)-(S)-HCQ, approximately), which were 
previously obtained by semipreparative HPLC (Cardoso, 
Bonato, 2005). The obtained results are described at Table 
TABLE I- Average concentrations of every enantiomer produced in the three optimization steps
(-)-(R)-DCQ (+)-(S)-DCQ (-)-(R)-DHCQ (+)-(S)-DHCQ
Conc. 
(ng mL-1)
RSD Conc. 
(ng mL-1)
RSD Conc. 
(ng mL-1)
RSD Conc. 
(ng mL-1)
RSD
A
30 387,44 2.3 148.16 11.5 505.94 2.3 179.80 7.0
A
90 388,63 6.5 182.12 10.6 589.95 5.4 169.71 9.5
A
180 383,56
b 7.4 238.93a 8.9 739.73a 3.1 233.33a 1.8
B
200 103,59 11.48 * * 230.77 9.43 * *
B
500 179,46 2.2 73.60 7.4 361.54 3.7 92.8 10.8
B
1000 378,72
a 11.9 229.45a 1.1 853.85a 10.0 330.44a 7.4
C
200 438,26 12.1 402.87 7.9 695.24
a 12.9 554.84 6.6
C
300 386,43 12.0 274.69 8.7 662.86 8.2 322.58 13.0
C
500 327,49
a 2.2 176.67a 13.3 695.24a 4.1 221.50a 13.1
C
1000 261,43 10.9 54.12 10.0 451.43 10.8 98.92 3.8
RSD, relative standard deviation, n = 3 for every condition, asignificant difference, bnon-significant difference. * Values below 
quantification limit
TABLE II- Average concentrations of every enantiomer in the experiments evaluating anesthetics and the effect of metabolism inducer
Tests
DCQ
 (-)-(R)- (+)-(S)-
DHCQ
 (-)-(R)- (+)-(S)-
Conc.
ng mL-1
RSD
Conc.
ng mL-1
 RSD
Conc.
ng mL-1
RSD
Conc.
ng mL-1
RSD
Ethyl Ether 417.13 10.2 158.74 13.1 800.00 13.1 217.02 13.9
Thiopental 112.91 12.6 104.16 3.6 214.81 4.9 97.87 6.2
With inducer 504.78 6.8 218.00 11.6 852.34 8.4 333.33 13.2
Without inducer 382.41 1.8 205.37 7.33 683.95 12.6 286.11 9.4
RSD, relative standard deviation, n = 3 for every condition.
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IV and the chromatograms representative of incubation are 
shown at Figure 2. The results show that the enantiomer 
(-)-(R)-HCQ is preferably metabolized, seeing that the 
proportions of concentration [(-)-(R)/ (+)-(S)] were 2.2 for 
the DCQ metabolite and 3.3 for the DHCQ metabolite; it 
was verified also that (-)-(R)-DHCQ is the main formed 
metabolite. The used method did not allow evaluating the 
formation of enantiomers of BDCQ metabolite.
In vivo studies developed with rats (Wey et al., 1995) 
showed higher concentrations of enantiomers (+)-(S)- of 
metabolites in total blood. Comparing our results with 
literature data, it was concluded that besides the stereo-
selective metabolism, other pharmacokinetic processes 
probably act on occasion of the drug administration.
Metabolism of HCQ employing the isolated 
microsomal fraction of mice liver
The same concentrations of racemic HCQ and isola-
ted enantiomers of the drug were used in this experiment. 
Chromatograms representative of incubation are shown 
at Figure 2. Table V shows the concentrations for the 
HCQ metabolites after incubation of racemic mixture and 
isolated enantiomers. Here the results were also obtained 
employing methodology developed by HPLC (Cardoso, 
Bonato, 2005).
For hepatic microsomes of mice, it was also verified 
that the enantiomer (-)-(R)- HCQ is preferably metaboli-
zed, being that the proportions of concentration [(-)-(R)/
(+)-(S)] were of 2.0 for the DCQ metabolite and 4.3 for 
the DHCQ metabolite. (-)-(R)-DHCQ represented also the 
main formed metabolite.
In the above developed experiments employing HPLC 
as analytical technique, it was not possible to evaluate the 
TABLE III. Optimized conditions for the in vitro study of 
metabolism
Anesthetic Ethylic ether
Volume of microsomal homogenate 500  mL
Incubation time 180 minutes
Racemic HCQ concentration 1000 mg mL-1
Volume of HCQ solution 10  mL
TABLE IV- Results of incubation of HCQ with microsomal fraction of rats liver
Metabolites DCQ (-) – (R)-  (+) – (S)- DHCQ (-) – (R)-  (+) – (S)-
Incubation Rac-HCQ
Conc. (ng mL-1) 273.43 124.67 667.35 200.56
RSD 
Proportion R/S
3.2 2.2 10.9 9.6 3.3 5.6
Incubation (-)-(R)-HCQ
Conc. (ng mL-1)  127.12  240.04
RSD 10.9 1.5
Incubation (+)-(S)-HCQ
 Conc. (ng mL-1)  61.08  84.96 a
RSD 13.2 14.5
n = 3 for every incubation; RSD, relative standard deviation; a, semiquantitative result, because this value is below of the method 
quantification limit.
FIGURE 2- Chromatograms of (A) incubation of microsomal 
fraction of rats liver with rac-HCQ and (B) incubation of 
microsomal fraction of mice liver. (-)-(R)-DCQ (1) and (+)-(S)-
DCQ (2), (-)-(R)-DHCQ (3) and (+)-(S)-DHCQ (4).
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formation of BDCQ metabolite. For simultaneous analysis 
of this and other metabolites, it was employed a method de-
veloped by CE (Cardoso et al., 2006). The in vitro study of 
metabolism was conducted with microsomal liver fractions 
of mice, with proteins concentration of 30.0 mg mL-1 and 
incubation with racemic HCQ (1000 mg mL-1). A represen-
tative electropherogram of incubation is shown at Figure 3 
and Table VI shows the concentration of HCQ metabolites 
after incubation of microsomal fraction with racemic HCQ.
The obtained results show again higher formation of 
metabolites originated from enantiomer (-)-(R)-HCQ and 
that the metabolite BDCQ is formed in lower proportion.
CONCLUSIONS
The (-)-(R)-HCQ is preferably metabolized by hepatic 
enzymes of rats and mice, resulting in higher concentrations 
for all isomers (-)-(R)- of metabolites. The DHCQ metabo-
lite represented the main formed metabolite, in the form 
of enantiomer (-)-(R)-. However, in vivo pharmacokinetic 
studies have shown (R)/(S) < 1 for the HCQ metabolites in 
human blood or rats blood serum (Wey et al., 1995; Duchar-
me et al., 1995; Mclachlan et al., 1993, 1994; Brocks et al., 
1992, 1994; Emami et al., 1998; Midha et al., 1996). So, 
considering the experiments described in this work, it could 
be suggested that another enantioselective process, besides 
mere metabolism, would be responsible by the enantioselec-
tive pharmacokinetics of HCQ. These considerations have 
also been reported for the CQ and emphasize the relevance 
of in vitro studies of metabolism for a complete understan-
ding of the drug kinetic disposition.
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